Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nuclear ribonucleoprotein polypeptide C pseudogene 16 (SNRPCP16) is a **pseudogene**—a genomic DNA sequence similar to a known gene but typically nonfunctional due to disablements such as frameshifts or premature stop codons. Unlike canonical protein targets, **pseudogenes like SNRPCP16 do not encode functional proteins and are generally not considered therapeutic targets**. Some pseudogenes may be transcribed and act in gene regulation—such as by generating noncoding RNAs or affecting parental gene expression via ceRNA or miRNA decoy mechanisms—but there is currently no evidence indicating SNRPCP16 functions or is implicated in disease processes. No drugs or biomarkers are known for SNRPCP16, and it should not be mistaken for an actionable or druggable target. **Key points:** - SNRPCP16 is not a receptor, enzyme, transporter, or transcription factor. - It is a noncoding pseudogene, typically lacking biological or therapeutic relevance. - "Is_incorrect" is true: This is not a conventional molecular drug target; it represents a nonfunctional or regulatory genomic sequence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nuclear ribonucleoprotein polypeptide C pseudogene 16 (SNRPCP16).